Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Alpha-1 Adrenergic Antagonist (1) ·
Beta Blocker (1) ·
Cardioselective (β1) + vasodilator (1) ·
Serotonin partial agonist reuptake inhibitor (SPARI) (1) ·
[[:Category:ACE_inhibitors|ACE inhibitor]] (1) ·
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (1) ·
[[:Category:Antidepressants|Antidepressant]] (1) ·
[[:Category:Antiemetics|Antiemetic]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (2) ·
[[:Category:Anxiolytics|Anxiolytic]] (1) ·
[[:Category:Corticosteroids|Corticosteroid]] (1) ·
[[:Category:Dopamine_D2_antagonists|Dopamine D2 antagonist]] (1) ·
[[:Category:Glucocorticoids|Glucocorticoid]] (1) ·
[[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]] (1) ·
[[:Category:Prokinetics|Prokinetic]] (1) ·
[[:Category:Selective Serotonin Reuptake Inhibitors (SSRIs)|SSRI]] (1)
mechanism:
None (5) ·
Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1) ·
The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) ·
TrkB/BDNF'"`UNIQ--ref-00000040-QINU`"' '"`UNIQ--vote-00000041-QINU`"' (1)
uses:
Major depressive disorder in adults (FDA-approved 2011) (1) ·
'"`UNIQ--vote-00000042-QINU`"', '"`UNIQ--vote-00000043-QINU`"', '"`UNIQ--vote-00000044-QINU`"' (1) ·
'"`UNIQ--vote-000001D9-QINU`"', '"`UNIQ--vote-000001DA-QINU`"', '"`UNIQ--vote-000001DB-QINU`"', '"`UNIQ--vote-000001DC-QINU`"' (1) ·
'"`UNIQ--vote-0000056B-QINU`"' (1) ·
'"`UNIQ--vote-0000059D-QINU`"' (1) ·
'"`UNIQ--vote-000005D0-QINU`"', '"`UNIQ--vote-000005D1-QINU`"', '"`UNIQ--vote-000005D2-QINU`"' (1) ·
'"`UNIQ--vote-00000B81-QINU`"', '"`UNIQ--vote-00000B82-QINU`"', '"`UNIQ--vote-00000B83-QINU`"' (1) ·
'"`UNIQ--vote-00000EF4-QINU`"', '"`UNIQ--vote-00000EF5-QINU`"', '"`UNIQ--vote-00000EF6-QINU`"', '"`UNIQ--vote-00000EF7-QINU`"', '"`UNIQ--vote-00000EF8-QINU`"' (1)
starting dose:
1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) ·
10 mg (1) ·
10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) ·
10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID (1) ·
20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed (1) ·
5 mg daily (1) ·
5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1) ·
Inhaled (Flovent HFA) 88 mcg BID; intranasal (Flonase) 2 sprays/nostril daily; topical (Cutivate) 0.05% cream BID (1)
preparations:
1, 2, 5 mg caps (1) ·
10 mg, 20 mg, 40 mg caps (1) ·
10 mg, 20 mg, 40 mg tablets (1) ·
2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) ·
2.5, 5, 10, 20 mg tabs (1) ·
5, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL IV; 15 mg/spray intranasal (1) ·
5, 20, 40 mg tablets (1) ·
Inhaled MDI 44/110/220 mcg per actuation; DPI (Diskus) 50/100/250 mcg; nasal spray 50 mcg/actuation; cream/ointment 0.005%, 0.05% (1)
fda max: (Click arrow to add another value)
routes:
onset:
None (1) ·
1–2 h (1) ·
30–90 min (1) ·
4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) ·
BP effect 1 hour; max at 4-6 hours (1) ·
BP effect 1-2 weeks; max at 2-3 weeks (1) ·
Inhaled: bronchial effect 1-2 weeks; nasal: symptom relief 12-24 hours; topical: hours (1) ·
IV/IM 1-3 minutes; PO 30-60 minutes (1)
duration:
halflife:
1–4 days (7–15 days for norfluoxetine) (1) ·
2–3 h (1) ·
5-6 hours'"`UNIQ--ref-00000EF9-QINU`"' (1) ·
~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) ·
~11 hours (enalaprilat, the active metabolite)'"`UNIQ--ref-00000B84-QINU`"' (1) ·
~13 hours'"`UNIQ--ref-0000056C-QINU`"' (1) ·
~25 hours (1) ·
~7.8 hours (fluticasone propionate, inhaled systemic exposure)'"`UNIQ--ref-000001DD-QINU`"' (1)
bioavailability:
70–90% (oral) (1) ·
<1% oral (extensive first-pass via CYP3A4); ~30% inhaled lung deposition'"`UNIQ--ref-000001DE-QINU`"' (1) ·
~12% (extensive metabolizers); ~96% (poor metabolizers) (1) ·
~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' (1) ·
~60% (1) ·
~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1) ·
~72% (with food); much lower fasting (~36%) (1) ·
~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"' (1)
pregnancy:
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-0000056E-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1) ·
Category C (2) ·
Category C'"`UNIQ--ref-00000045-QINU`"' (1) ·
Inhaled and intranasal generally considered safe; widely used in asthma in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh benefits/risks (1) ·
Widely used for hyperemesis gravidarum; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
OTC (intranasal Flonase) and [[USLegal:Prescription only|Rx-only]] (inhaled, topical) in US (1) ·
Rx (1) ·
Rx-only in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US (3) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for '''tardive dyskinesia''' (irreversible movement disorder), driving the 12-week chronic-use limit'"`UNIQ--ref-00000EFB-QINU`"' (1)
Showing below up to 8 results in range #1 to #8.